XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Collaboration Agreements (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
program
target
Jul. 31, 2020
USD ($)
Jun. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative                  
Revenue       $ 5,599   $ 4,490 $ 10,908 $ 8,410  
Upfront payment received     $ 15,000            
Maximum | Sales based                  
Collaborative Arrangement and Arrangement Other than Collaborative                  
Amount receivable for achievement of milestones     165,000            
Maximum | Research Development And Regulatory                  
Collaborative Arrangement and Arrangement Other than Collaborative                  
Amount receivable for achievement of milestones     $ 245,000            
Eli Lilly                  
Collaborative Arrangement and Arrangement Other than Collaborative                  
Number of additional targets | target   3              
Number of programs | program   6              
Number of targets | target   5              
Deferred revenue       309,800     309,800   $ 319,800
Revenue       5,200   4,200 10,000 8,000  
Upfront payment received $ 300,000           300,000    
Cost Sharing Allocation   50.00%              
Eli Lilly | Sales Based Milestone                  
Collaborative Arrangement and Arrangement Other than Collaborative                  
Amount receivable for achievement of milestones   $ 180,000              
Optout milestone receivable upon achievement   360,000              
Eli Lilly | Maximum | Research Development And Regulatory                  
Collaborative Arrangement and Arrangement Other than Collaborative                  
Amount receivable for achievement of milestones   10,000              
Optout milestone receivable upon achievement   $ 70,000              
Merck                  
Collaborative Arrangement and Arrangement Other than Collaborative                  
Unsatisfied portion of the performance obligation       16,100     16,100   $ 17,000
Merck | Research Development And Regulatory                  
Collaborative Arrangement and Arrangement Other than Collaborative                  
Amount receivable for achievement of milestones       240,000     240,000    
Merck | Merck Collaboration Agreement                  
Collaborative Arrangement and Arrangement Other than Collaborative                  
Revenue       $ 400   $ 300 $ 1,000 $ 400  
Payment received for achievement of milestones         $ 5,000